Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Apr 15;4(4):CD000249.
doi: 10.1002/14651858.CD000249.pub2.

Antifibrinolytics for heavy menstrual bleeding

Alison C Bryant-Smith  1 , Anne Lethaby, Cindy Farquhar, Martha Hickey
Affiliations
Meta-Analysis

Antifibrinolytics for heavy menstrual bleeding

Alison C Bryant-Smith et al. Cochrane Database Syst Rev. .

Abstract

Background: Heavy menstrual bleeding (HMB) is an important physical and social problem for women. Oral treatment for HMB includes antifibrinolytic drugs, which are designed to reduce bleeding by inhibiting clot-dissolving enzymes in the endometrium.Historically, there has been some concern that using the antifibrinolytic tranexamic acid (TXA) for HMB may increase the risk of venous thromboembolic disease. This is an umbrella term for deep venous thrombosis (blood clots in the blood vessels in the legs) and pulmonary emboli (blood clots in the blood vessels in the lungs).

Objectives: To determine the effectiveness and safety of antifibrinolytic medications as a treatment for heavy menstrual bleeding.

Search methods: We searched the Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO and two trials registers in November 2017, together with reference checking and contact with study authors and experts in the field.

Selection criteria: We included randomized controlled trials (RCTs) comparing antifibrinolytic agents versus placebo, no treatment or other medical treatment in women of reproductive age with HMB. Twelve studies utilised TXA and one utilised a prodrug of TXA (Kabi).

Data collection and analysis: We used standard methodological procedures expected by Cochrane. The primary review outcomes were menstrual blood loss (MBL), improvement in HMB, and thromboembolic events.

Main results: We included 13 RCTs (1312 participants analysed). The evidence was very low to moderate quality: the main limitations were risk of bias (associated with lack of blinding, and poor reporting of study methods), imprecision and inconsistency.Antifibrinolytics (TXA or Kabi) versus no treatment or placeboWhen compared with a placebo, antifibrinolytics were associated with reduced mean blood loss (MD -53.20 mL per cycle, 95% CI -62.70 to -43.70; I² = 8%; 4 RCTs, participants = 565; moderate-quality evidence) and higher rates of improvement (RR 3.34, 95% CI 1.84 to 6.09; 3 RCTS, participants = 271; moderate-quality evidence). This suggests that if 11% of women improve without treatment, 43% to 63% of women taking antifibrinolytics will do so. There was no clear evidence of a difference between the groups in adverse events (RR 1.05, 95% CI 0.93 to 1.18; 1 RCT, participants = 297; low-quality evidence). Only one thromboembolic event occurred in the two studies that reported this outcome.TXA versus progestogensThere was no clear evidence of a difference between the groups in mean blood loss measured using the Pictorial Blood Assessment Chart (PBAC) (MD -12.22 points per cycle, 95% CI -30.8 to 6.36; I² = 0%; 3 RCTs, participants = 312; very low quality evidence), but TXA was associated with a higher likelihood of improvement (RR 1.54, 95% CI 1.31 to 1.80; I² = 32%; 5 RCTs, participants = 422; low-quality evidence). This suggests that if 46% of women improve with progestogens, 61% to 83% of women will do so with TXA.Adverse events were less common in the TXA group (RR 0.66, 95% CI 0.46 to 0.94; I² = 28%; 4 RCTs, participants = 349; low-quality evidence). No thromboembolic events were reported in any group.TXA versus non-steroidal anti-inflammatory drugs (NSAIDs)TXA was associated with reduced mean blood loss (MD -73.00 mL per cycle, 95% CI -123.35 to -22.65; 1 RCT, participants = 49; low-quality evidence) and higher likelihood of improvement (RR 1.43, 95% CI 1.18 to 1.74; 12 = 0%; 2 RCTs, participants = 161; low-quality evidence). This suggests that if 61% of women improve with NSAIDs, 71% to 100% of women will do so with TXA. Adverse events were uncommon and no comparative data were available. No thromboembolic events were reported.TXA versus ethamsylateTXA was associated with reduced mean blood loss (MD 100 mL per cycle, 95% CI -141.82 to -58.18; 1 RCT, participants = 53; low-quality evidence), but there was insufficient evidence to determine whether the groups differed in rates of improvement (RR 1.56, 95% CI 0.95 to 2.55; 1 RCT, participants = 53; very low quality evidence) or withdrawal due to adverse events (RR 0.78, 95% CI 0.19 to 3.15; 1 RCT, participants = 53; very low quality evidence).TXA versus herbal medicines (Safoof Habis and Punica granatum)TXA was associated with a reduced mean PBAC score after three months' treatment (MD -23.90 pts per cycle, 95% CI -31.92 to -15.88; I² = 0%; 2 RCTs, participants = 121; low-quality evidence). No data were available for rates of improvement. TXA was associated with a reduced mean PBAC score three months after the end of the treatment phase (MD -10.40 points per cycle, 95% CI -19.20 to -1.60; I² not applicable; 1 RCT, participants = 84; very low quality evidence). There was insufficient evidence to determine whether the groups differed in rates of adverse events (RR 2.25, 95% CI 0.74 to 6.80; 1 RCT, participants = 94; very low quality evidence). No thromboembolic events were reported.TXA versus levonorgestrel intrauterine system (LIUS)TXA was associated with a higher median PBAC score than TXA (median difference 125.5 points; 1 RCT, participants = 42; very low quality evidence) and a lower likelihood of improvement (RR 0.43, 95% CI 0.24 to 0.77; 1 RCT, participants = 42; very low quality evidence). This suggests that if 85% of women improve with LIUS, 20% to 65% of women will do so with TXA. There was insufficient evidence to determine whether the groups differed in rates of adverse events (RR 0.83, 95% CI 0.25 to 2.80; 1 RCT, participants = 42; very low quality evidence). No thromboembolic events were reported.

Authors' conclusions: Antifibrinolytic treatment (such as TXA) appears effective for treating HMB compared to placebo, NSAIDs, oral luteal progestogens, ethamsylate, or herbal remedies, but may be less effective than LIUS. There were too few data for most comparisons to determine whether antifibrinolytics were associated with increased risk of adverse events, and most studies did not specifically include thromboembolism as an outcome.

PubMed Disclaimer

Conflict of interest statement

AB‐S, AL and CF have no conflicts of interest to declare. MH's institution has received funding from Bayer Schering Pharma for research into the mechanisms of abnormal uterine bleeding with fibroids.

Figures

1
1
Study flow diagram (PRISMA chart).
2
2
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
3
3
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Bonnar 1996 {published and unpublished data}
    1. Bonnar J, Sheppard B. Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ 1996;313(7057):579‐82. - PMC - PubMed
Callender 1970 {published data only}
    1. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal 1970;4(5729):214‐6. - PMC - PubMed
Edlund 1995 {published and unpublished data}
    1. Edlund M, Andersson K, Rybo G, Lindoff CC, Astedt B, Schoult BV. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology 1995;102(11):913‐7. - PubMed
Fathima 2012 {published data only}
    1. Fathima A, Sultana A. Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine 2012;4(3):e315‐22.
Freeman 2011 {published data only}
    1. Freeman EW, Lukes A, VanDrie D, Mabey RG, Gersten J, Adomako TL. A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology 2011;205(4):319.e1‐319.e7. - PubMed
Goshtasebi 2013 {published data only}
    1. Goshtasebi A, Moukhah S, Gandevani SB. Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics 2013;288(5):1055‐60. - PubMed
Goshtasebi 2015 {published data only}
    1. Goshtasebi A, Mazari Z, Behboudi Gandevani S, Naseri M. Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran 2015;29:199. - PMC - PubMed
Jaisamrarn 2006 {published data only}
    1. Jaisamrarn U, Sitavarin S, Suwikrom S, Kamolpornwijit W. Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83.
Kiseli 2016 {published data only}
    1. Kiseli M, Kayikcioglu F, Evliyaoglu O, Haberal A. Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation 2016;81(5):447‐53. - PubMed
Kriplani 2006 {published data only}
    1. Kriplani A, Kulshrestha V, Agarwal N, Diwakar S. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology 2006;26(7):673‐8. - PubMed
Lukes 2010 {published data only}
    1. Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology 2010;116(4):865‐75. - PubMed
Preston 1995 {published data only}
    1. Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology 1995;102(5):401‐6. - PubMed
Zhang 2008 {published data only}
    1. Zhang Y, He F, Sun Z, LI S, Bi S, Huang X, et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology 2008;43(4):247‐50. - PubMed

References to studies excluded from this review

Andersch 1988 {published data only}
    1. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstetricia et Gynecologica Scandinavica 1988;67(7):645‐8. - PubMed
Chamberlain 1991 {published data only}
    1. Chamberlain G, Freeman R, Price F, Kennedy A, Green D, Eve L. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology 1991;98(7):707‐11. - PubMed
Drosdal 1993 {published and unpublished data}
    1. Drosdal H. Treatment of menorrhagia with tranexamic acid. A clinical trial of an underestimated problem in general practice. Tidsskrift for Den Norske Laegeforening 1993;113(23):2907‐10. - PubMed
Harrison 1976 {published data only}
    1. Harrison RF, Campbell S. A double‐blind trial of ethamsylate in the treatment of primary and intrauterine device menorrhagia. Lancet 1976;2(7980):283‐5. - PubMed
Kasonde 1975 {published data only}
    1. Kasonde JM, Bonnar J. Effect of ethamsylate and aminocaproic acid on menstrual blood loss in women using intrauterine devices. British Medical Journal 1975;4(5987):21‐2. - PMC - PubMed
Kouides 2009 {published data only}
    1. Kouides PA, Byams VR, Phillip CS, Stein SF, Heit JA, Lukes AS, et al. Multisite management study of menorrhagia with abnormal haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. British Journal of Haematology 2009;145(2):212‐20. - PubMed
Moghtadaei 2012 {published data only (unpublished sought but not used)}
    1. Moghtadaei P. Different medication [sic] for heavy menstrual bleeding. 3rd International and 18th National Congress of Iranian Society for Reproductive Medicine; 2012. 2012:42.
Muse 2010 {published data only}
    1. Muse K, Gersten J, Waldbaum A, Mabey RG, Lukes A, Moore K. Long‐term quality of life and safety of a new tranexamic acid menorrhagia treatment. Fertility and Sterility 2010;94(4):S13.
Najam 2010 {published data only}
    1. Najam R, Agarwal D, Tyagi R, Singh S. Comparison of tranexamic acid with a combination of tranexamic acid and mefenamic acid in reducing menstrual blood loss in ovulatory dysfunctional uterine bleeding (DUB). Journal of Clinical and Diagnostic Research 2010;4(5):3020‐5.
NCT01190150 {unpublished data only}
    1. NCT01190150. Lysteda Pediatric Research Equity Act (PREA) pharmacokinetic study in adolescent females with heavy menstrual bleeding. clinicaltrials.gov/ct2/show/NCT01190150 (first received 27 August 2010).
NCT01428713 {unpublished data only}
    1. NCT01428713. Tranexamic acid (TA) vs combined oral contraceptive (COCP) pilot study. clinicaltrials.gov/ct2/show/NCT01428713 (first received 5 September 2011).
NiIsson 1965 {published data only}
    1. Nilsson L, Rybo G. Treatment of menorrhagia with epsilon aminocaproic acid. A double blind investigation. Acta Obstetricia et Gynecologica Scandinavica 1965;44(3):467‐73. - PubMed
Nilsson 1967 {published data only}
    1. Nilsson L, Rybo G. Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA). Acta Obstetricia et Gynecologica Scandinavica 1967;46:572‐80.
Petersen 1983 {published data only}
    1. Petersen K, Jelert H, Diernaes E, Detlefsen GU. Treatment of hypermenorrhea with tranexamic acid [Behandling af hypermenore med traneksamsyre]. Ugeskrift for Laeger 1983;145(36):2759‐60. - PubMed
Tabatabaei 2013 {published data only (unpublished sought but not used)}
    1. Tabatabaei A. A clinical randomized single blind trial of medical therapies for menorrhagia using ibuprofen and tranexamic acid. International Journal of Fertility and Sterility 2013;7:120.
Vermylen 1968 {published data only}
    1. Vermylen J, Verhaegen‐Declercq ML, Verstraete M, Fierens F. A double blind study of the effect of tranexamic acid in essential menorrhagia. Bulletin de la Societe Royale Belge de Gynecologie et d'Obstetrique 1968;38:385‐90. - PubMed
    1. Vermylen J, Verhaegen‐Declercq ML, Verstraete M, Fierens F. A double blind study of the effect of tranexamic acid in essential menorrhagia. Thrombosis et Diathesis Haemorrhagica 1968;20:583‐7. - PubMed
Westrom 1970 {published data only}
    1. Bengtsson LP, Westrom L. Treatment by tranexamic acid in menorhagia in women using intrauterine devices. Lakartidningen 1971;68(33):3685‐91. - PubMed
    1. Westrom L, Bengtsson LP. Effect of tranexamic acid (AMCA) in menorrhagia with intrauterine contraceptive devices. Journal of Reproductive Medicine 1970;5:154‐61. - PubMed
Ylikorkala 1983 {published data only}
    1. Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics & Gynaecology 1981;90:78‐83. - PubMed

Additional references

Berntorp 2001
    1. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thrombosis and Haemostasis 2001;86(2):714‐5. - PubMed
Butt 2012
    1. Butt JL, Jeffery ST, Spuy ZM. An audit of indications and complications associated with elective hysterectomy at a public service hospital in South Africa. International Journal of Gynaecology and Obstetrics 2012;116(2):112‐6. - PubMed
Duckitt 2012
    1. Duckitt K, Collins S. Menorrhagia. BMJ Clinical Evidence 2012;01:805. - PMC - PubMed
Edlund 2003
    1. Edland M, Blomback M, He S. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coagulation & Fibrinolysis 2003;14(6):593‐8. - PubMed
El‐Hemaidi 2007
    1. El‐Hemaidi I, Gharaibeh A, Shehata H. Menorrhagia and bleeding disorders. Current Opinion in Obstetrics & Gynecology 2007;19(6):513‐20. - PubMed
Fender 1999
    1. Fender GRK, Prentice A, Gorst T, Nixon RM, Duffy SW, Day NE, et al. Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ 1999;318(7193):1246‐50. - PMC - PubMed
Fox 2012
    1. Fox K. Management of heavy menstrual bleeding in general practice. Current Medical Research and Opinion 2012;28(9):1517‐25. - PubMed
Grant 2000
    1. Grant C, Gallier L, Fahey T, Pearson N, Sarangi J. Management of menorrhagia in primary care ‐ impact on referral and hysterectomy: data from the Somerset Morbidity Project. Journal of Epidemiology and Community Health 2000;54(9):709‐13. - PMC - PubMed
Gupta 2013
    1. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J. Levonogestrel intrauterine system versus medical therapy for menorrhagia. New England Journal of Medicine 2013;368(2):128‐37. - PubMed
Hallberg 1964
    1. Hallberg L, Nilsson L. Determination of menstrual blood loss. Scandinavian Journal of Clinical and Laboratory Investigation 1964;16:244‐8. - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org.
Higham 1990
    1. Higham J, O'Brien P, Shaw R. Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology 1990;97:734‐9. - PubMed
Kaunitz 2010
    1. Kaunitz A. A new treatment for menorrhagia enters the US market. OBG Management 2010;22(6):34‐5.
Leminen 2012
    1. Leminen H, Hurskainen R. Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety. International Journal of Women's Health 2012;4:413‐21. - PMC - PubMed
Lumsden 2011
    1. Lumsden MA, Wedisinghe L. Tranexamic acid for heavy menstrual bleeding. Expert Opinion on Pharmacotherapy 2011;12(13):2089‐95. - PubMed
Marret 2010
    1. Marret H, Fauconnier A, Chabbert‐Buffet N, Cravello L, Golfier F, Gondry J, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. European Journal of Obstetrics & Gynecology and Reproductive Biology 2010;152(2):133‐7. - PubMed
Matteson 2013
    1. Matteson K, Rahn D, Wheeler T, Casiano E, Siddiqui N, Harvie H, et al. Nonsurgical management of heavy menstrual bleeding. Obstetrics and Gynecology 2013;121(3):632‐43. - PMC - PubMed
Munro 2011
    1. Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM‐COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynecology and Obstetrics 2011;113(1):3‐13. - PubMed
Naoulou 2012
    1. Naoulou B, Tsai M. Efficacy of tranexamic acid in the treatment of idiopathic and non‐functional heavy menstrual bleeding: a systematic review. Acta Obstetricia et Gynecologica Scandinavica 2012;91(5):529‐37. - PubMed
NICE 2007
    1. Royal College of Obstetricians and Gynaecologists. Heavy menstrual bleeding. National Institute for Health and Clinical Excellence; 2007 January.
NICE 2016
    1. Royal College of Obstetricians and Gynaecologists. Heavy menstrual bleeding. National Institute for Health and Clinical Excellence; 2016 August.
Qiu 2014
    1. Qiu J, Cheng J, Wang Q, Hua J. Levonogestrel‐releasing intrauterine system versus medical therapy for menorrhagia: a systematic review and meta‐analysis. Medical Science Monitor 2014;20:1700‐13. - PMC - PubMed
Singh 2013
    1. Singh S, Best C, Dunn S, Lyeland N, Wolfman WL. Medical treatment. Journal of Obstetrics and Gynaecology Canada 2013;35(5):S12‐7. - PubMed
Turner 2000
    1. Turner E, Bowie P, Kellock C. First‐line management of menorrhagia: findings from a survey of general practitioners in Forth Valley. British Journal of Family Planning 2000;26(4):227‐8. - PubMed
Warner 2004
    1. Warner PE, Critchley HOD, Lumsden MA, Campbell‐Brown M, Douglas A, Murray GD. Menorrhagia II: Is the 80mL blood loss criterion useful in management of complaint of menorrhagia?. American Journal of Obstetrics and Gynecology 2004;190(5):1224‐9. - PubMed
Zakherah 2011
    1. Zakherah M, Sayed G, El‐Nashar A, Shaaban M. Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecologic and Obstetric Investigation 2011;71(4):281‐4. - PubMed

References to other published versions of this review

Lethaby 2000
    1. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD000249] - DOI - PubMed

MeSH terms